G E N O M I C D I AG N O S T I C D E V I C E M A N U FAC T U R E R I N - V I T R O D I A G N O S T I C ( I V D ) D E V I C E MEVOPURTM Laser-Transmitting and Laser-Absorbing Pre-color Solution AV I E N T S O L U T I O N • Customized solutions - Quality-by-Design (QdB) approach • Optimized pigment / additive selection – good distribution in final part minimizes welding failure • Mitigated contamination and extractable risk on incoming raw material with control based on fingerprinting • Ensured uninterrupted supply from multiple ISO13485-2016 certified sites • Minimized risk of change with change control agreements W H Y AV I E N T K E Y R E Q U I R E M E N T S P R O D U C T I V I T Y & Q U A L I T Y • Good weldability, low rejection rate • Solutions in wide range of polymers, colors and transparency • Pre-tested ingredients to biocompatibility and extractable metals L E A R N M O R E https://www.avient.com/products/polymer-additives/performance-enhancement-additives/mevopur-functional-additives

D is t. ) K W R P P G A V Y F U L R P M G C P F M C H X L H U N E C L A S H E M N C E S C L Source: Peer data per Bloomberg market data as of October 25, 2021 Avient reflects 2021 estimated revenue of $4,750M and estimated CAPEX of $80M (excludes one-time synergy capture CAPEX of $20M) Avient Specialty Formulators Other Chemical/Specialty Companies Free Cash Flow Conversion (1) 2021E (%) Being asset light helps us to generate strong free cash flow that is in line with specialty formulators. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA H I G H F R E E C A S H F L OW C O N V E R S I O N Avient reflects 2021 estimated EBITDA of $580M and estimated CAPEX of $80M (excludes one-time synergy capture CAPEX of $20M) Source: Peer data per Bloomberg market data as of October 25, 2021 86 92 85 82 79 77 74 89 83 82 80 79 79 78 78 72 33 A vi e n t K W R P P G A V Y F U L R P M G C P F M C U N V R C E H X L B N R A S H E C L E M N H U N S C L A L B (12) Source: Peer data per Bloomberg market data as of October 25, 2021 Total Enterprise Value / 2021E EBITDA Our current valuation with updated guidance implies an EBITDA multiple that is below specialty formulator peers and the median of other selected chemical / specialty companies. With the Clariant Color business acquisition and divestment of the PP&S business, our exposure is now concentrated in less-cyclical and high-growth markets, with increased geographic diversification and a more specialized portfolio that can significantly expand EBITDA margins. 24 Avient reflects 2021 estimated EBITDA of $580M O U R VA LUATI O N V E R S U S P E E R S Avient Specialty Formulators Other Chemical/Specialty Companies 11.0 18.3 16.3 15.4 14.5 11.6 11.1 36.2 28.0 24.9 13.0 11.5 11.3 10.0 9.2 8.8 7.7 6.7 A vi e n t K W R P P G A V Y R P M F U L G C P A L B H X L E C L A S H F M C B N R S C L U N V R E M N C E H U N S U M M A RY: W H Y I N V E S T I N AV I E N T ?

W H AT W E D O : M AT E R I A L S C I E N C E 4 CUSTOM FORMULATION We sell solutions not commodities. D is t. ) K W R P P G A V Y F U L R P M G C P F M C H X L H U N E C L A S H E M N C E S C L Source: Peer data per Bloomberg market data as of November 8, 2021 Avient reflects 2021 estimated revenue of $4,750M and estimated CAPEX of $80M (excludes one-time synergy capture CAPEX of $20M) Avient Specialty Formulators Other Chemical/Specialty Companies Free Cash Flow Conversion (1) 2021E (%) Being asset light helps us to generate strong free cash flow that is in line with specialty formulators. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA H I G H F R E E C A S H F L OW C O N V E R S I O N Avient reflects 2021 estimated EBITDA of $580M and estimated CAPEX of $80M (excludes one-time synergy capture CAPEX of $20M) Source: Peer data per Bloomberg market data as of November 8, 2021 86 93 85 83 79 77 75 89 85 83 81 79 79 78 77 74 25 A vi e n t K W R P P G A V Y F U L R P M G C P F M C U N V R C E B N R H X L A S H E C L E M N H U N S C L A L B (10) Source: Peer data per Bloomberg market data as of November 8, 2021 Total Enterprise Value / 2021E EBITDA Our current valuation with updated guidance implies an EBITDA multiple that is below many of our specialty formulator peers.

Microsoft PowerPoint - AVNT Q4 2022 Earnings Presentation AVIENT CORPORATION F O U R T H Q U A R T E R 2 0 2 2 R E S U L T S A N D 2 0 2 3 F I N A N C I A L G U I D A N C E (NYSE: AVNT) F E B R U A R Y 1 5 , 2 0 2 3 D I S C L A I M E R Forward-Looking Statements Certain statements contained in or incorporated by reference into this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. EPS (1) $0.14 $2.67 $3.04 2006 2018 2022PF TO P- TI E R S U S TA I N A B I L I T Y P E R F O R M A NC E A N D R E C O G N I T I O N Industry Sustainability Standards 90th percentile 84th ESG Ratings Performance 3 1 4 10 PEOPL E C U L T U R E I S E V E R Y T H I N G Community Service 7x Safer than Industry Average World-Class Safety Leadership Development Over $17 million raised since 2010 Diversity & Inclusion 11 2 0 2 2 R E S U L T S Q4 EBITDA BRIDGE ( P R O F O R M A T O TA L C O M PA N Y ) 13 $ millions CAI: Price / Mix 42 Inflation (20) SEM: Price / Mix 14 Inflation (10) Net Price Benefit 26 Wage and Energy Inflation (13) Clariant Color Integration Synergies 4 Incentives, Other Employee Costs 21 FX (10) Q4 2022 $107 Adjusted EBITDA Q4 2021 $ 132 Demand (50) Russia Import Sales (3) • Demand contraction especially prevalent in EMEA and Asia • Pricing continues to cover inflation of raw materials, wages and energy P ROV E N T R AC K R E C O R D O F S T RO N G A N D I M P ROV I N G F R E E C A S H F LOW G E N E R AT I O N 14 • Periods of economic weakness have driven higher levels of cash generation due to working capital management • Anticipate continued strong free cash flow generation and conversion despite global uncertainty 78% 78% 80% 80% 81% 78% 84% 83% 80% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 2014 2015 2016 2017 2018 2019 2020 2021 2022 0 50 100 150 200 250 300 350 400 F re e C a s h F lo w C o n v e rs io n F re e C a s h F lo w FCF $ AVNT FCF Conversion % S&P FCF Conversion % Note: Free cash flow conversion calculated as (Adjusted EBITDA – Capex) / Adjusted EBITDA. 2020 is pro forma for Clariant Color and 2022 is pro forma for Avient Protective Materials Avient Specialty Formulators Other Specialty / Chemical Companies 2023E(%) 28 79 87 81 79 76 73 90 77 76 75 73 64 59 33 A vi e n t K W R P P G F U L A V Y R P M F M C C E A S H H X L E C L H U N E M N S C L M U LT I P L E E X PA N S I O N Avient Specialty Formulators Other Specialty / Chemical Companies Source: Peer data per Bloomberg as of February 13, 2023 Note: Avient reflects 2023 adjusted EBITDA guidance of $530M and closing share price of $38.89.

Cesa Fiber Additives for Heat Preservation Technical Bulletin_TW2.28-1 Cesa™ 紅外蓄熱纖維添加劑 熱影像圖片 加熱前表面溫度：20.22°C 技術公告 埃萬特推出新一代應用於紡織纖維的紅外蓄熱添加 劑配方，旨在幫助品牌商能夠更加輕鬆地滿足消費 者對冬裝、運動裝和床上用品輕量舒適的要求。 • • • 測試方法：FTTS-FA-010-2007 4.2 設備：紅外線熱像儀 熱源：500W鹵素燈 熱輻射距離：100 cm 加入Cesa紅外蓄熱纖維添加劑 加熱10分鐘後表面溫度：33.85°C 溫度變化：+13.6°C 測試方法 0.9 9°C 8.9°C 5.6°C 0.625 +12.9% +13.6% +1.7% www.avient.com 標準要求 測試結果 GB/T 30127 遠紅外線性能 GB/T 18319-2019 光蓄熱性能 FTTS-FA-010 紅外線性能及蓄熱升溫 GB/T 11048-2008 Method A 熱舒適性 熱阻性能 單位：CLO 人體生理實驗 遠紅外線發射率 ≥0.88 (5-14um) （測試溫度:34°C） 遠紅外線輻射溫升值 ≥1.4°C 最高允許溫升值 ≥6°C 平均溫升值 ≥4.4°C（20分鐘） 平均發射率 ≥ 0.8 (2-22um) （測試溫度: 25°C) 0.81 規定加熱ΔT ≥ 0.5°C （相對於標準） +5.34°C (ΔT) 裸體：0 內褲：0.04 T恤：0.09 厚毛衣：0.35 冬季大衣：0.7 上述所有資料均為參考值 血流量 血流速 血氧濃度（%SpO2） 請聯絡您的埃萬特業務代表以了解 您所在國家或地區是否有售。

© 2019, All Right Reserved Avient Corporation, 33587 Walker Road, Avon Lake, Ohio USA 44012 LED LIGHT MANUFACTURER H E A T E X C H A N G E R F O R A N E L E C T R O N I C C I R C U I T B O A R D • Looking to replace aluminum • Reduce corrosion • Light weighting • Eliminated the effects of corrosion • Provided a lightweight alternative to aluminium • Redesigned the part for easier processing and further weight reduction • Enabled the customer to take a new, innovative product in to the market Therma-Tech™ Thermally Conductive Formulation KEY REQUIREMENTS WHY AVIENT?

AVIENT SOLUTION V E H I C L E B AT T E RY M A N U FA C T U R E R C E L L P A C K C O O L I N G T U B E • Comply with ISO 3384-1:2011 for TPE compression set • Comply with ISO 11359-2:1999 standard for linear thermal expansion • Good ethanediol resistance • Good sealing performance • Customized a Shore 60A hardness TPE formulation with good physical property retention • Achieved good compression set and bonding performance with PA12 • Qualified thermal expansion by customer • Provided excellent ethanediol resistance under both low and high temperature conditions KEY REQUIREMENTS CHEMICAL RESISTANCE + SEALING LEARN MORE OnFlex™ TPE Custom Formulation Copyright © 2023, Avient Corporation.

W H AT W E D O : M AT E R I A L S C I E N C E 5 CUSTOM FORMULATION We sell solutions not commodities. D is t. ) K W R R P M P P G A V Y F U L G C P F M C H X L IF F F O E H U N E C L K R A E M N A S H C E S C L G R A A L B Median: 5%Median: 3% Source: Peer data per Bloomberg market data as of March 12, 2021 Avient reflects 2021 estimated revenue of $4,100M and excludes one-time synergy capture CAPEX ($20M) Avient Specialty Formulators Other Chemical/Specialty Companies Free Cash Flow Conversion (1) 2021E (%) Being asset light helps us to generate strong free cash flow that is in line with specialty formulators. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA Median: 84% Median: 77% H I G H F R E E C A S H F L OW C O N V E R S I O N Avient reflects 2021 estimated EBITDA of $510M and excludes one-time synergy capture CAPEX ($20M) Source: Peer data per Bloomberg market data as of March 12, 2021 85 89 86 86 82 80 76 89 85 83 82 81 78 77 77 76 75 73 70 69 49 19 A vi e n t K W R P P G R P M A V Y F U L G C P F M C IF F H X L U N V R E C L A S H B N R F O E E M N C E G R A H U N K R A S C L A L B Source: Peer data per Bloomberg market data as of March 12, 2021 Total Enterprise Value / 2021E EBITDA Our current valuation implies an EBITDA multiple that is below specialty formulator peers and some of our more highly valued chemical peers.

W H AT W E D O : M AT E R I A L S C I E N C E 4 CUSTOM FORMULATION We sell solutions not commodities. D is t. ) K W R P P G F U L R P M A V Y F M C H U N H X L S C L E C L E M N C E A S H Source: Peer data per Bloomberg market data as of February 15, 2022. O U R VA LUATI O N V E R S U S P E E R S Avient Specialty Formulators Other Chemical/Specialty Companies 5.4 8.5 10.1 10.0 15.7 15.0 14.2 12.7 10.2 25.0 19.7 17.7 13.2 12.3 10.0 9.9 8.9 8.5 8.3 6.6 A vi e n t (2 0 1 1 ) A vi e n t (2 0 1 6 ) A vi e n t (2 0 2 1 ) A vi e n t (T o d a y) R P M K W R P P G A V Y F U L A L B E C L H X L A S H F M C B N R E M N U N V R C E S C L H U N Historic Multiple S U M M A RY: W H Y I N V E S T I N AV I E N T ?

KEY CHARACTERISTICS • Manufactured at four ISO 13485 certified sites, providing global consistency and increased security of supply • Documented change control beyond CAS number, reducing risk of change • Non-phthalate and formulated without animal-derived substances • Color can be combined with additives to enhance performance and protection REGULATORY SUPPORT • Raw materials tested to: - ISO 10993-1 and USP biological evaluation - European Pharmacopeia 3.1.3/3.1.5 (polyolefin) - USP (polyethylene) - ICH Q3D elemental impurities • Registered Device Master File • Food contact established with FDA/EU* NOMINAL OUTSIDE DIAMETER OF NEEDLE (MM) COLOR DESCRIPTION RAL PANTONE TRANSPARENT PRODUCT CODE OPAQUE PRODUCT CODE 0.4 Medium Grey 7035 423 C PP7M665125 PP7M665127 0.45 Brown 8017 7588 C PP8M665294 PP8M665296 0.5 Orange 2003 173 C PP2M665298 PP2M665300 0.55 Medium Purple 4005 7676 C PP4M665290 PP4M665292 0.6 Deep Blue 5010 288 C PP5M665894 PP5M665896 0.7 Black 9005 Black C PP9M664950 PP9M664952 0.8 Deep Green 6001 7483 C PP6M665687 PP6M665689 0.9 Yellow 1021 115 C PP1M665211 PP1M665213 1.1 Cream 1015 7401 C PP0M665290 PP0M665292 1.2 Pink 3015 502 C PE3M665725 PP3M665727 Healthcare use limitations apply—see below.